Association Review
In brief
The association between MAP2K1 (Mitogen-Activated Protein Kinase Kinase 1) and Glioma is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
0
Compounds
2
Trials
12of 295 via MAP2K1 compounds
Publications
0
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
1 database identifier
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Population genetics
GWAS signals
1 GWAS phenotype
Gene-associated GWAS phenotypes matching the disorder, with best SNP, score, risk-allele frequency and effect size.
Request access
06
Interventions
Therapeutics
2 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials
295 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
08
Provenance
References & sources
7 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access